ANGO Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -14.4% compared to AngioDynamics, Inc.'s net margin of -12425.36%. AngioDynamics, Inc.'s return on equity of -17.24% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

AngioDynamics, Inc. has a consensus price target of $19.33, signalling upside risk potential of 41.95%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 414.97%. Given that Perspective Therapeutics, Inc. has higher upside potential than AngioDynamics, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than AngioDynamics, Inc..

AngioDynamics, Inc. has a beta of 0.489, which suggesting that the stock is 51.142% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

AngioDynamics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

AngioDynamics, Inc. quarterly revenues are $75.7M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. AngioDynamics, Inc.'s net income of -$10.9M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, AngioDynamics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics, Inc. is 1.86x versus 162.05x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Masimo Corp. has a net margin of -14.4% compared to AngioDynamics, Inc.'s net margin of 14.46%. AngioDynamics, Inc.'s return on equity of -17.24% beat Masimo Corp.'s return on equity of -19.18%.

AngioDynamics, Inc. has a consensus price target of $19.33, signalling upside risk potential of 41.95%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 29.17%. Given that AngioDynamics, Inc. has higher upside potential than Masimo Corp., analysts believe AngioDynamics, Inc. is more attractive than Masimo Corp..

AngioDynamics, Inc. has a beta of 0.489, which suggesting that the stock is 51.142% less volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.

AngioDynamics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics, Inc. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.

AngioDynamics, Inc. quarterly revenues are $75.7M, which are smaller than Masimo Corp. quarterly revenues of $371.5M. AngioDynamics, Inc.'s net income of -$10.9M is lower than Masimo Corp.'s net income of $53.7M. Notably, AngioDynamics, Inc.'s price-to-earnings ratio is -- while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics, Inc. is 1.86x versus 4.50x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of -14.4% compared to AngioDynamics, Inc.'s net margin of 7.29%. AngioDynamics, Inc.'s return on equity of -17.24% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

AngioDynamics, Inc. has a consensus price target of $19.33, signalling upside risk potential of 41.95%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that AngioDynamics, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe AngioDynamics, Inc. is more attractive than Phibro Animal Health Corp..

AngioDynamics, Inc. has a beta of 0.489, which suggesting that the stock is 51.142% less volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

AngioDynamics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. AngioDynamics, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

AngioDynamics, Inc. quarterly revenues are $75.7M, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. AngioDynamics, Inc.'s net income of -$10.9M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, AngioDynamics, Inc.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics, Inc. is 1.86x versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of -14.4% compared to AngioDynamics, Inc.'s net margin of 17.41%. AngioDynamics, Inc.'s return on equity of -17.24% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

AngioDynamics, Inc. has a consensus price target of $19.33, signalling upside risk potential of 41.95%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $346.07 which suggests that it could grow by 21.72%. Given that AngioDynamics, Inc. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe AngioDynamics, Inc. is more attractive than West Pharmaceutical Services, Inc..

AngioDynamics, Inc. has a beta of 0.489, which suggesting that the stock is 51.142% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

AngioDynamics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.3% to investors and pays a quarterly dividend of $0.22 per share. AngioDynamics, Inc. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

AngioDynamics, Inc. quarterly revenues are $75.7M, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. AngioDynamics, Inc.'s net income of -$10.9M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, AngioDynamics, Inc.'s price-to-earnings ratio is -- while West Pharmaceutical Services, Inc.'s PE ratio is 42.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics, Inc. is 1.86x versus 6.86x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.